RxDoctor Payments Data

Stacy Schamp

Family · Paris, TNNPI 1003118019

Payments from drug & device makers

$2,695in general payments, 2019–2025

Across 52 payments — averaging $51.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • Sumitomo Pharma America, Inc.$276
  • Axonics, Inc.$213
  • Johnson & Johnson$171
  • Teleflex LLC$110
  • Endo USA, Inc.$104
  • plus $307 from 12 others

What the payments were for

  • Travel & lodging$1,07740%
  • Food & beverage$1,61860%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,695 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$31,486
Medicare patients
304
Services billed
1,237

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron15$10,684
Trimethoprim25$977
Estradiol14$624
NitrofurantoinNitrofurantoin Macrocrystal38$557
Cephalexin106$530
Albuterol Sulfate HfaAlbuterol Sulfate32$506
Solifenacin Succinate17$494
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst32$434
Tamsulosin Hcl32$403
Oxybutynin Chloride ErOxybutynin Chloride12$352
Fluconazole24$210
Azithromycin39$181
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav15$170
Cefdinir11$167
Levofloxacin25$164

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$276$10,68415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Paris

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →